'Reasonable' pricing could limit the cost for Zolgensma in France - STAT

'Reasonable' pricing could limit the cost for Zolgensma in France - STAT

Why didn’t nonprofits and the NIH require ‘reasonable’ pricing for Zolgensma? That may happen in France

By JAMES LOVE

NOVARTIS VIA AP

Zolgensma, a treatment for SMA, costs $2.1 million in the U.S. Thanks to a French nonprofit's reasonable pricing clause, it may be much cheaper in France.

READ MORE